The DEA's broader marijuana rescheduling proceeding remains stalled following a late-September 2026 stay granted by Chief Administrative Law Judge Derek Julius. Opponents cited a new GAO report questioning federal agencies' drug-scheduling policies and requested supplemental briefing, prompting the pause with government responses due by October 13. An 11-day evidentiary hearing concluded in July after post-hearing briefs, yet no recommended decision has issued. While certain state-licensed medical and FDA-approved cannabis products moved to Schedule III in April 2026, the remaining adult-use market stays in Schedule I pending a final DEA rule. These accumulated procedural steps and recent delays explain the low implied probabilities for full rescheduling by year-end.